- Case report
- Open Access
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C
© Srinivas et al; licensee BioMed Central Ltd. 2007
- Received: 19 October 2006
- Accepted: 12 April 2007
- Published: 12 April 2007
Co-infection with falciparum malaria and leptospirosis is uncommon. The aim of this study is to report a case of severe sepsis secondary to dual infection with falciparum malaria and leptospirosis. The literature is also reviewed on the clinical course of such co-infections, and the possible mechanisms and treatment of patients with life-threatening malaria and leptospirosis with activated protein C. The patient was a 25-year old male admitted in the Respiratory Intensive Care Unit (RICU) with fever, haemolysis, acute renal failure, hepatitis, acute lung injury (ALI) and altered sensorium. A syndromic evaluation was done and investigations revealed falciparum parasitaemia. He was treated with parenteral artesunate, ceftriaxone and doxycycline, and adjunctive therapies as for severe sepsis. Infusion of activated protein C was started 20 hours after onset of organ dysfunction, and intensive haemodialysis was instituted. Over the next four days the patient became afebrile with progressive resolution of ALI, renal failure and hepatitis. His Leptospira serology (requested as part of the evaluation) was reported positive on day 5. Dual infections are common and under-recognized in the tropics. Failure to treat potential co-infections may lead to poor outcomes. Acute lung injury in falciparum malaria has high mortality rates and therapy as for severe sepsis may improve survival. Adjunctive therapies, including activated protein C, cannot replace source eradication.
- Severe Sepsis
- Acute Lung Injury
- Falciparum Malaria
- Severe Malaria
The world-wide distribution of malaria  overlaps with that of other infectious diseases, including leptospirosis. Co-infection of malaria with a wide variety of infectious diseases has been reported. Co-infection of malaria with leptospirosis is rare and has been only been reported in seven (two definite and five probable) cases . Clinical features are unreliable to separate single from dual infections because of the markedly similar clinical syndrome. Patients with dual infections have a severe clinical presentation and their clinical course may be worsened by lack of appropriate therapy for both [2, 3]. Patients with severe falciparum malaria, especially those with acute lung injury, have a high mortality rate. Falciparum malaria is due to sequestration of parasites in visceral capillaries with endothelial dysfunction and leptospirosis is an infectious vasculitis; as a result, therapies which improve endothelial function might positively impact the clinical outcomes of both diseases. Newer adjuncts are needed because of the present high mortality rates and the limited benefit conferred by current ancillary therapies. Activated protein C (aPC) has anti-thrombotic, pro-fibrinolytic and anti-inflammatory properties and confers a relative mortality reduction of 22% in patients with severe sepsis and ≥ 2 organ dysfunction [4, 5] and has recently been reported to be beneficial in severe falciparum malaria [6, 7] and leptospirosis . This is the first reported case of severe sepsis secondary to falciparum malaria with leptospirosis co-infection, with good response to aPC in addition to standard care. Despite the potential benefits of this therapy, source eradication with appropriate antibiotic therapy is paramount. Data on the use of aPC in severe malaria or severe leptospirosis needs to be generated urgently, but ancillary therapies cannot replace the role of syndromic evaluation and therapy.
Physiological and clinical variables during first 7 days of RICU stay demonstrating the effect of the infusion of Drotrecogin alfa (activated) on days 1–4.
Heart rate (/minute)
Respiratory rate (/minute)
PEEP (cm H20)
Serum creatinine (mg/dL)
Urine output (mL/24 hours)
Serum bilirubin (mg/dL)
Total leucocyte count (/μL)
Platelet count (/μL)
There are about 500 million estimated cases of malaria, with 2–3 million severe malaria cases and 1.1 million deaths each year worldwide . Leptospirosis is an increasingly recognized infection in the tropics. Presence of the causative agent, farming, poor sanitation and hygiene provide the substrate for the observed seasonal epidemics. However, the infection is under-recognized because most infections are anicteric, resolve spontaneously and mimic other febrile illnesses.
In a patient with fever, renal failure and jaundice the differential diagnosis include severe malaria, severe leptospirosis, enteric fever, Hantaan virus, viral hepatitis with fulminant liver failure and scrub typhus [9, 10]. The local epidemiology, presence of haemolysis and lung injury in this patient restricted the differential diagnosis to malaria, leptospirosis, typhoid and viral hepatitis (especially HEV related). These entities may be impossible to resolve clinically and empiric therapy to cover all of these is justified initially because of the turn-around time of investigations in the tropics. The patient was started on artesunate, ceftriaxone and doxycycline accordingly. In a patient with renal failure and hyperparasitaemia, artesunate has the advantage of rapidity of action, smaller infusion volumes, lesser toxicity and a mortality reduction of 34.7%. In patients with severe leptospirosis, doxycycline is as efficacious as penicillin and is therapeutic for scrub typhus as well.
As malaria and leptospirosis are common in the tropics, co-infections are expected to be common. However such a scenario has seldom been reported [2, 13]. This may be due to the unavailability of assays for leptospirosis in resource-constrained areas and failure to anticipate co-infections because of the overlapping clinical features. A significant number of unanticipated co-infections have been reported when routine syndromic serologic panels were employed . Failure to recognize acute leptospirosis co-infection causes delay in the initiation of directed therapy and potentially preventable excess mortality. IgM ELISA antibodies become detectable by the end of first week and have replaced MAT (macro-agglutination test) for routine diagnosis because of the early seroconversion, availability of commercial bedside kits and excellent sensitivity and specificity . Although this patient had a modified Faine score  of 31 (with > 25 presumptive of leptospirosis), the validity of this score in co-infections has not been evaluated. Given the clinical features and high specificity of IgM ELISA and unavailability of MAT, the diagnosis of leptospirosis is highly probable.
Acute respiratory distress syndrome in falciparum malaria has an incidence of 21% in those with severe malaria requiring hospitalization . Mortality may be as high as 30% in this group and a high frequency of bacterial super-infections occur . Pulmonary lesions in leptospirosis are primarily haemorrhagic with an incidence from 20–70%. The extent of involvement may have no relation to the presence of icterus and may be self-limited or extensive and fatal.
In patients with severe falciparum malaria, extensive organ sequestration may lead to endothelial clogging and dysfunction. Microthrombosis and vasospasm due to endothelial dysfunction lead to organ hypo-perfusion and worsening lactic acidosis. Adjunctive therapies like exchange transfusion  and anti-oxidants have shown no survival advantage . Leptospirosis is an infectious vasculitis with the potential to accentuate endothelial dysfunction in co-infections. At the time of evaluation of this patient, a MEDLINE search and communication with manufacturers (Eli Lilly) revealed no reported data on the use of aPC in malaria or leptospirosis. Subsequently, five cases of successful use of aPC in severe malaria and one in leptospirosis has been reported . This remains the first report of complicated dual infection treated with aPC. As the parasitaemia cleared in less than 36 hours of onset of illness (due to early artesunate institution) exchange transfusion was not contemplated . He had worsening organ dysfunction and was initiated on an infusion of drotrecogin alpha 24 μg/kg/hr for 96 hours and antibiotics. Initiation was guided by the time to establishment of organ(s) failure and was before 48 hours from the first organ failure . Drotrecogin alfa treatment has been shown to reduce mortality in patients with severe sepsis and has been approved for the treatment of patients with severe sepsis who have two or more organ dysfunction and/or APACHE II scores more than 25 , and may have a role in complicated tropical infections as well . An improvement in respiratory function and more rapid resolution of cardiovascular dysfunction has been demonstrated. Most of these activities appear to involve the modulation of endothelial function, modulation of leukocyte activity, and improvement in microvascular perfusion in severe sepsis, thus improving organ function . In contrast to sepsis of other aetiologies, the intense endothelial clogging by malaria and denudation due to leptospirosis may have contributed to a slower response. A similar delayed response has been observed in another reported case . Large trials of use of aPC in malaria and leptospirosis, though urgently needed, are unlikely to be conducted given the costs involved. Lack of evidence of benefit is not evidence of lack of benefit and the use of aPC in severe falciparum malaria and leptospirosis is justified pending large trials for the same. Source control represents a key component of success therapy in sepsis and is the best way to quickly reduce parasitic or bacterial load . The appropriate institution of antimicrobials guided by clinical judgment is thus paramount and cannot be replaced by ancillary therapies.
Dual infections are common and under-recognized in the tropics. Clinical features are unreliable to separate single infections from dual infections, which may have a severe clinical course. Both falciparum malaria and leptospirosis are associated with significant endothelial dysfunction and therapies that improve endothelial function might positively impact clinical outcomes of both diseases. aPC has anti-thrombotic, pro-fibrinolytic and anti-inflammatory properties which can improve endothelial function. Despite the potential benefits of this therapy, source eradication with appropriate antibiotic therapy is paramount. Data on the use of aPC in severe malaria or severe leptospirosis needs to be generated urgently but the role of syndromic evaluation and empiric therapy must not be relegated.
- Beales PF, Warrell DA: Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000, 94 (suppl 1): 1-90.Google Scholar
- Wongsrichanalai C, Murray CK, Gray M, Miller RS, MCDaniel P, Liao WJ, Pickard AL, Magill AJ: Co-infection of malaria and leptospirosis. Am J Trop Med Hyg. 2003, 68: 583-585.PubMedGoogle Scholar
- Murray CK, Ellis MW, Hospenthal DR: Susceptibility of leptospira serovars to anti-malarial agents. Am J Trop Med Hyg. 2004, 71: 685-686.PubMedGoogle Scholar
- Bernard G, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Rodriguez AL, Steingrub JS, Garber GE: Efficacy and safety of recombinant human recombinant protein C for severe sepsis. The recombinant human recombinant protein C worldwide evaluation in severe sepsis(PROWESS) study group. N Engl J Med. 2001, 344: 699-708. 10.1056/NEJM200103083441001.View ArticlePubMedGoogle Scholar
- Agarwal R, Nath A: Activated protein C in sepsis: down but not out, yet. Crit Care. 2006, 10: 416-10.1186/cc4988.PubMed CentralView ArticlePubMedGoogle Scholar
- Kendrick BJL, Gray AG, Pickworth A, Watters MPR: Drotrecogin alfa (activated) in severe falciparum malaria. Anaesthesia. 2006, 61: 899-902. 10.1111/j.1365-2044.2006.04752.x.View ArticlePubMedGoogle Scholar
- Kapadia F, Shirwadkar C: Drotrecogin alfa in tropical infections and refractory multi-organ failure. Intensive Care Med. 2006, 32: 1281-1282. 10.1007/s00134-006-0230-6.View ArticlePubMedGoogle Scholar
- Greenwood BM, Bojang K, Whitty CJM, Targett GAT: Malaria. Lancet. 2005, 365: 1487-1498. 10.1016/S0140-6736(05)66420-3.View ArticlePubMedGoogle Scholar
- Sharma A, Mahajan S, Gupta ML, Kanga A, Sharma V: Investigation of an outbreak of scrub typhus in the Himalayan region of India. Jpn J Infect Dis. 2005, 58: 208-210.PubMedGoogle Scholar
- Bacaner N, Wilson ME: Evaluation of the ill returned traveller. Clinics in Family Practice. 2005, 7: 805-834.Google Scholar
- White NJ: South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-725. 10.1016/S0140-6736(05)67761-6.View ArticlePubMedGoogle Scholar
- Hoontrakoon S, Suputtamongkol Y: Exchange transfusion as an adjunct to the treatment of severe falciparum malaria. Trop Med Int Health. 1998, 3: 156-161. 10.1111/j.1365-3156.1998.00198.x.View ArticlePubMedGoogle Scholar
- Chaudhry R, Premlatha MM, Mohanty S, Dhawan B, Singh KK, Dey AB: Emerging leptospirosis, North India. Emerg Infect Dis. 2002, 8: 1527-View ArticleGoogle Scholar
- Gupta N, Sambasiva RR, Bhalla P, Agarwal SK: Serodiagnosis of leptospirosis in Delhi using IgM enzyme linked immunosorbent assay. Indian J Med Res. 2004, 120: 557-558.PubMedGoogle Scholar
- Kumar SS, Shareek PS: Diagnosis of leptospirosis utilizing modified Faine's criteria. J Assoc Physic India. 2004, 52: 678-679.Google Scholar
- Taylor WR, White NJ: Malaria and the lung. Clin Chest Med. 2002, 23: 457-468. 10.1016/S0272-5231(02)00004-7.View ArticlePubMedGoogle Scholar
- Rajput R, Singh H, Singh S, Meena , Tiwari UC: Pulmonary manifestations in malaria. J Indian Med Assoc. 2000, 98: 612-614.PubMedGoogle Scholar
- Riddle MS, LJackson J, Sanders JW: Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin Infect Dis. 2002, 34: 1192-1198. 10.1086/339810.View ArticlePubMedGoogle Scholar
- Pasvol G: Management of severe malaria:Interventions and controversies. Infect Dis Clin N Am. 2005, 19: 211-240. 10.1016/j.idc.2004.10.007.View ArticleGoogle Scholar
- Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JS: New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Critical Care. 2005, 9 (suppl 4): S38-S45. 10.1186/cc3747.PubMed CentralView ArticlePubMedGoogle Scholar
- Marshall JC, Maier RV, Jimenez M, Dellinger P: Source control in the management of severe sepsis and septic shock: an evidence based review. Crit Care Med. 2004, 32 (suppl): S513-523. 10.1097/01.CCM.0000143119.41916.5D.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.